Anticipated $0.62 EPS for Teva Pharmaceutical Industries Limited (TEVA) on May, 10

May 3, 2018 - By Jeanette Garcia

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Corporate Logo

On May, 10 Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s earnings report is expected by WallStreet, as reported by Faxor. Analysts predict $0.62 earnings per share. That’s $0.41 down or 39.81 % from 2017’s earnings of $1.03. This could hit $631.29 million profit for TEVA assuming the current $0.62 earnings per share will become reality. Last quarter $0.91 earnings per share was reported. Analysts forecasts -31.87 % negative EPS growth this quarter. The stock decreased 1.94% or $0.36 during the last trading session, hitting $18.24.Teva Pharmaceutical Industries Limited is downtrending after having declined 49.50% since May 3, 2017. TEVA has 23.10M volume or 83.79% up from normal. TEVA underperformed the S&P500 by 61.05%.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

In total 24 analysts cover Teva Pharmaceutical Industries Ltd (NYSE:TEVA). “Buy” rating has 5, “Sell” are 7, while 12 are “Hold”. 21% are bullish. 45 are the (NYSE:TEVA)’s analyst reports since November 6, 2017 according to StockzIntelligence Inc. On Thursday, February 15 the rating was maintained by Mizuho with “Buy”. On Wednesday, January 31 Guggenheim maintained the shares of TEVA in report with “Hold” rating. On Tuesday, November 7 the firm has “Reduce” rating by HSBC given. The stock rating was maintained by Oppenheimer with “Hold” on Tuesday, January 23. On Tuesday, January 9 the firm earned “Buy” rating by Mizuho. On Friday, January 26 the company was maintained by Leerink Swann. On Friday, November 17 Mizuho maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) with “Neutral” rating. On Tuesday, December 12 the company was initiated by Guggenheim. On Tuesday, January 16 the stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Hold” rating given by Guggenheim. On Friday, February 9 the stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Hold” rating by RBC Capital Markets.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.The company has $18.57 billion market cap. It operates through two divisions, Generic Medicines and Specialty Medicines.Currently it has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: